Candel Therapeutics Cash Flow Statement
NASDAQ: CADLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
9.94+0.28 (+2.90%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Candel Therapeutics free cash flow
In fiscal 2025, Candel Therapeutics generated -$38.3 million of operating cash flow and spent $587,000 on capital expenditures. That left free cash flow of -$38.9 million.
Summary generated from market data by MetaCap's automated system. Methodology
Candel Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Net Income | -38.18M | -55.18M | -37.94M | -18.79M | -36.12M | -17.68M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| Depreciation & Amortization | 845.00K | 990.00K | 960.00K | 778.00K | 232.00K | 91.00K |
| Stock-Based Compensation | 3.82M | 5.31M | 3.09M | 2.31M | 2.96M | 2.11M |
| Change in Working Capital | 3.21M | 625.00K | -564.00K | 535.00K | -1.37M | 1.74M |
| Operating Cash Flow | -38.31M | -27.02M | -34.24M | -31.42M | -22.22M | -9.07M |
| Capital Expenditures | -587.00K | -16.00K | -457.00K | -1.30M | -1.83M | -1.48M |
| Investing Cash Flow | -560.00K | -16.00K | -280.00K | -1.30M | -1.83M | 38.45M |
| Debt Issued | 47.95M | — | — | — | — | — |
| Financing Cash Flow | 56.10M | 94.28M | -121.00K | 19.97M | 71.80M | 490.00K |
| Net Change in Cash | 17.23M | 67.24M | -34.65M | -12.74M | 47.75M | 29.87M |
| Free Cash Flow | -38.90M | -27.04M | -34.70M | -32.72M | -24.05M | -10.55M |
This table shows 6 annual periods of Candel Therapeutics's cash flow statement, from FY 2025 back to FY 2020, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CADL's reporting calendar. What is a cash flow statement?